Adagene Inc
ADAG1.959USD
+0.039+2.03%
交易中 （美東）報價延遲15分鐘
115.35M總市值
--本益比TTM
關於 Adagene Inc 公司
天演藥業是一家平臺驅動的臨牀階段生物製藥公司，致力於推動新型抗體類癌症免疫療法的發現和開發。公司主要從事癌症單克隆抗體藥物的研發和生產。公司的主要產品包括：ADG106 正在開發用於治療晚期實體瘤和非霍奇金淋巴瘤（NHL）。ADG126 旨在解決與現有已獲批准的 CTLA-4 免疫腫瘤療法的 MOA 相關的毒性和療效問題，並擴大 CTLA-4 作爲癌症治療靶點的潛力。ADG116 旨在靶向 CTLA-4 的獨特保守表位。以及 ADG104，一種針對 PD-L1 的單特異性抗體，正在中國同時進行 Ib 期和 II 期臨牀試驗。
公司簡介
公司代碼ADAG
公司名稱Adagene Inc
上市日期Feb 09, 2021
CEODr. Peter (Peizhi) Luo, Ph.D.
員工數量138
證券類型Depository Receipt
年結日Feb 09
公司地址4F, Building C14, No. 218, Xinghu Street
城市SUZHOU
上市交易所NASDAQ Global Market Consolidated
國家China
郵編- -
電話8651287773632
網址https://www.adagene.com/
公司代碼ADAG
上市日期Feb 09, 2021
CEODr. Peter (Peizhi) Luo, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Yuwen Liu
Ms. Yuwen Liu
Independent Director
Independent Director
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
收入明細
FY2024
FY2023
FY2022
FY2021
FY2020
暫無數據
地區USD
名稱
營收
佔比
China (Mainland)
103.20K
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
WuXi AppTec Co, Ltd.
8.45%
General Atlantic LLC
8.12%
Olive Tree Capital
7.57%
HSG Holding Ltd.
2.85%
Luo (Peter)
2.77%
Other
70.23%
持股股東
持股股東
佔比
WuXi AppTec Co, Ltd.
8.45%
General Atlantic LLC
8.12%
Olive Tree Capital
7.57%
HSG Holding Ltd.
2.85%
Luo (Peter)
2.77%
Other
70.23%
股東類型
持股股東
佔比
Investment Advisor
17.67%
Private Equity
8.12%
Venture Capital
7.57%
Individual Investor
2.77%
Corporation
1.93%
Investment Advisor/Hedge Fund
0.02%
Other
61.91%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
32
17.95M
38.09%
-2.89M
2025Q1
34
22.22M
47.17%
+1.25M
2024Q4
30
19.43M
43.91%
+6.91M
2024Q3
29
16.58M
37.45%
+3.51M
2024Q2
30
13.07M
29.54%
-384.35K
2024Q1
31
14.15M
32.04%
+4.42M
2023Q4
27
7.53M
17.08%
-3.44M
2023Q3
33
8.73M
19.93%
-2.62M
2023Q2
35
8.75M
19.96%
-2.76M
2023Q1
46
8.82M
20.14%
-5.30M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
WuXi AppTec Co, Ltd.
3.98M
8.45%
--
--
Mar 31, 2025
General Atlantic LLC
3.83M
8.12%
--
--
Mar 31, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Mar 31, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Fidelity International
749.45K
1.59%
-2.53M
-77.11%
Mar 31, 2025
Fidelity Management & Research Company LLC
473.95K
1.01%
-707.69K
-59.89%
Jun 30, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Mar 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
